# Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

> **NCT04491370** · PHASE1,PHASE2 · RECRUITING · sponsor: **New York Medical College** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Lymphoma
- Burkitt Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Transformed Non-Hodgkin Lymphoma
- Richter Syndrome
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Polatuzumab vedotin

## Key facts

- **NCT ID:** NCT04491370
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2026-08-15
- **Final completion:** 2027-08-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04491370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04491370, "Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04491370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*